Nancy M King
Overview
Explore the profile of Nancy M King including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
14
Citations
615
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
King N
Perspect Biol Med
. 2018 Oct;
61(3):450-464.
PMID: 30293981
The origins and aspirations of institutional review boards (IRBs), the American oversight system for research with human subjects, are well known, and their failures have been documented and disputed for...
2.
Mittal S, Bandaranayake R, King N, Prabu-Jeyabalan M, Nalam M, Nalivaika E, et al.
J Virol
. 2013 Feb;
87(8):4176-84.
PMID: 23365446
Drug resistance occurs through a series of subtle changes that maintain substrate recognition but no longer permit inhibitor binding. In HIV-1 protease, mutations at I50 are associated with such subtle...
3.
King N, Prabu-Jeyabalan M, Bandaranayake R, Nalam M, Nalivaika E, Ozen A, et al.
ACS Chem Biol
. 2012 Jun;
7(9):1536-46.
PMID: 22712830
The development of HIV-1 protease inhibitors has been the historic paradigm of rational structure-based drug design, where structural and thermodynamic analyses have assisted in the discovery of novel inhibitors. While...
4.
Ali A, Bandaranayake R, Cai Y, King N, Kolli M, Mittal S, et al.
Viruses
. 2011 Oct;
2(11):2509-2535.
PMID: 21994628
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of...
5.
Bandaranayake R, Kolli M, King N, Nalivaika E, Heroux A, Kakizawa J, et al.
J Virol
. 2010 Jul;
84(19):9995-10003.
PMID: 20660190
The majority of HIV-1 infections around the world result from non-B clade HIV-1 strains. The CRF01_AE (AE) strain is seen principally in Southeast Asia. AE protease differs by approximately 10%...
6.
Prabu-Jeyabalan M, King N, Nalivaika E, Heilek-Snyder G, Cammack N, Schiffer C
Antimicrob Agents Chemother
. 2006 Mar;
50(4):1518-21.
PMID: 16569872
In our previous crystallographic studies of human immunodeficiency virus type 1 (HIV-1) protease-substrate complexes, we described a conserved "envelope" that appears to be important for substrate recognition and the selection...
7.
Surleraux D, de Kock H, Verschueren W, Pille G, Maes L, Peeters A, et al.
J Med Chem
. 2005 Mar;
48(6):1965-73.
PMID: 15771440
On the basis of structural data gathered during our ongoing HIV-1 protease inhibitors program, from which our clinical candidate TMC114 9 was selected, we have discovered new series of fused...
8.
Surleraux D, Tahri A, Verschueren W, Pille G, de Kock H, Jonckers T, et al.
J Med Chem
. 2005 Mar;
48(6):1813-22.
PMID: 15771427
The screening of known HIV-1 protease inhibitors against a panel of multi-drug-resistant viruses revealed the potent activity of TMC126 on drug-resistant mutants. In comparison to amprenavir, the improved affinity of...
9.
Prabu-Jeyabalan M, Nalivaika E, King N, Schiffer C
J Virol
. 2004 Oct;
78(22):12446-54.
PMID: 15507631
Maturation of human immunodeficiency virus (HIV) depends on the processing of Gag and Pol polyproteins by the viral protease, making this enzyme a prime target for anti-HIV therapy. Among the...
10.
King N, Prabu-Jeyabalan M, Nalivaika E, Schiffer C
Chem Biol
. 2004 Oct;
11(10):1333-8.
PMID: 15489160
Drug resistance is a major obstacle in modern medicine. However, resistance is rarely considered in drug development and may inadvertently be facilitated, as many designed inhibitors contact residues that can...